Abrocitinib for atopic dermatitis after biologic therapy
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had eczema for at least 1 year.
- You are 12 years or older.
- Your eczema is moderate to severe and diagnosed by a skin specialist.
- You have tried 1 or 2 biologic therapies (like shots or infusions) and they either didn't work well or caused side effects.
- You are willing to take abrocitinib as prescribed and come to clinic visits as usual.
- You have not used abrocitinib or any similar JAK inhibitor pill before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study tests whether gradually lowering the dose of abrocitinib can keep your eczema under control while reducing side effects. It is for people with moderate-to-severe eczema who have already been on abrocitinib 200 mg daily for at least 3 months and whose skin is currently well controlled.
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
This study compares the effectiveness of a pill (upadacitinib) with several biologic injections (biologics are medicines that target specific parts of the immune system) in controlling moderate-to-severe atopic dermatitis (eczema). The goal is to see which treatment helps people achieve minimal disease activity, meaning their eczema is under good control.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.